Physician profile
Maite Talbott
NPI 1184615692
$30,218.59
in general payments reported to CMS, 2019-2025
24 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,218 · 2020: $158 · 2021: $577 · 2022: $1,150 · 2023: $1,409 · 2024: $15K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $6,060 · Travel and Lodging: $3,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,890.00 |
| Food and Beverage | $6,060.05 |
| Travel and Lodging | $3,165.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $21,417.30 | 2021-2025 | Valtoco |
| Livanova USA, INC. | $2,152.02 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,955.56 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $852.59 | 2022-2025 | |
| Sk Life Science, INC. | $705.34 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $607.38 | 2019-2023 | Qelbree |
| Neuropace, INC. | $564.70 | 2019-2024 | |
| Immedica Pharma US, INC. | $321.25 | 2022-2025 | Ztalmy |
| Greenwich Biosciences, INC. | $309.54 | 2020-2021 | |
| Medtronic USA, INC. | $204.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $198.10 | 2019-2022 | |
| Biomarin Pharmaceutical INC. | $183.49 | 2023-2025 | Brineura |
| Biocodex, INC. | $158.07 | 2023-2025 | Diacomit |
| Aquestive Therapeutics, INC. | $126.99 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $83.56 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $73.43 | 2023-2025 | Eprontia, Zonisade |
| Monteris Medical Corporation | $64.25 | 2021 | |
| Zimmer Biomet Holdings, INC. | $56.67 | 2019 | |
| Acadia Pharmaceuticals INC | $40.51 | 2023-2025 | Daybue |
| Upsher-Smith Laboratories LLC | $35.47 | 2022-2024 | |
| Eisai INC. | $31.38 | 2020-2022 | |
| Pyros Pharmaceuticals, INC. | $31.25 | 2024 | Vigpoder |
| Corium, LLC | $25.19 | 2025 | Azstarys |
| Neos Therapeutics, Lp | $20.23 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maite Talbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.